Every year, approximately 30 million infants are born in regions of Africa at risk for malaria infection. Without specific treatment for these vulnerable infants, malaria can quickly lead to complications and become fatal.
Until now, treatments have only been approved for infants weighing more than 4.5 kilograms, resulting in a significant treatment gap.
On July 8, 2025, Novartis announced that Swissmedic had approved Coartem® Baby (Riamet® Baby) as the first malaria medication specifically for newborns and young infants.
Infants Can Now Receive Targeted Malaria Treatment
EMS Calls to Schools Usually Result in Hospital Transport
Trauma was more common among elementary school-age students, while psychiatric conditions/substance abuse seen more frequently among adolescents
American Academy of Pediatrics Sues HHS Over Vaccine Policy
AAP maintains RFK Jr. violated federal law by unilaterally changing COVID-19 vaccine recommendations without scientific evidence